Meta-analyses and the 2023 guidelines of the European Society of Cardiology (ESC) further reinforce this trend by designating a Class I recommendation for SGLT2i and GLP-1 receptor agonists (GLP-1RAs) in patients with established atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes, irrespective of their degree of glycemic control [21,22,23]. Here, GLP1R is linked to type 2 diabetes mellitus.